Kornimate/medical-research-clean huggingface dataset:
influence of different doses of the vitamin b12 on recurrent aphthous stomatitis

Conditions: Recurrent Aphthous Stomatitis

Summary: background: the frequency of recurrent aphthous stomatitis (ras), the most common oral mucosa lesions seen in primary care, is up to 25% in the general population. sublingual vitamin b12 treatment, 1000 mcg per day for 6 months was found to be effective for patients suffering from ras, regardless of the serum vitamin b12 level. however, the optimal therapeutic dose of vitamin b12 treatment remains unclear. working hypothesis and aims: aim-to assesses the influence of different vitamin b12 treatment doses on the frequency and severity of ras episodes. working hypothesis- the group receiving the higher dose of vitamin b12 treatment will have the lower frequency and severity of ras episodes; the reaction will be faster. methods: randomized, double blind, intervention study. study population: 75 patients in three groups (total of 225 patients): group i- will receive sublingual vitamin b12 treatment, 1000 mcg per day for 6 months group ii- will receive sublingual vitamin b12 treatment, 100 mcg per day for 6 months group i- will receive sublingual vitamin b12 treatment, 2000 mcg per day for 6 months study design: study participates will be followed through three study periods: the first period- three months prior to receiving active treatment, the second period- six month of active treatment (with randomization to study groups), and the third period- three month after finishing active treatment. frequency and severity of ras episodes will be recorded by the patient with "aphthous diary" that will be filled daily during all study period (12 months). expected results: this study will allow us to identify optimal dose of vitamin b12 treatment that will achieve faster and longer remission of ras episodes. importance: this is a very common problem in the population. study results will help to identify optimal doses of vitamin b12 needed to treat ras. probable implications to medicine: study results are supposed to give faster and better treatment for ras episodes


Eligibility criteria:
inclusion criteria: * patients aged 18 and older * suffer from ras for at least one year, with aphthous frequency at least once a month. exclusion criteria: * known sensitivity to vitamin b12 * don't speak hebrew, russian or english. * systemic diseases, known in developing mouth aphthous (behcet disease, lupus erythematosus, rheumatoid arthritis and aids disease) * patients who have received last year any form of vitamin b12 . * patients who receive a different treatment to ras(not for pain) * pregnant or breastfeeding women * patient suffering from leber's optic atrophy * patients who suffer from psychosis

Keywords: vitamin b12 aphthous stomatitis cobalamin doses
developmental phenomenology of obsessive compulsive disorder and tourette syndrome in children and adolescents

Conditions: Tourette Syndrome; Obsessive Compulsive Disorder

Summary: objectives: i. characterize the natural history, associated features, and severity of symptoms of obsessive compulsive disorder and tourette syndrome in children and adolescents. ii. identify factors that influence the clinical course and prognosis of these patients.

protocol outline: all patients and their families participate in 6 parts of the study: current severity of symptoms, coincident disease diagnoses, natural history, neuropsychologic assessment, physical and neurologic assessment, and family history and function. the evaluations include the following: current severity of symptoms assessment, children's yale brown obsessive compulsive scale (cy-bocs), clinician's global impression-obsessive compulsive disorder (cgi-oc), leyton obsessional inventory-child version (loi-cv), obsessive compulsive personality rating scale, yale global tic severity scale(ygtss), clinician's global impression-tourette syndrome (cgi-ts), tourette syndrome symptom list (tssl), clinician's global impression-anxiety (cgi-a), covi anxiety scale (cas), children's manifest anxiety scale-revised (cmas-r), social anxiety scale for children-revised, fear survey schedule for children-revised, louisville fear survey, children's depression rating scale-revised (cdrs-r), clinician's global impression-depression (cgi-d), children's depression inventory (cdi), the dimensions of temperament survey (dots), mosher guilt scale-revised, real vs. ideal self questionnaire, harter self-perception profile for children, the children's global assessment scale (cgas), the child behavior checklist (cbcl), coincident disease diagnoses assessment, diagnostic interview schedule for children-ii (disc-ii), yale best estimate of diagnoses schedule (y-beds), natural history evaluation, yale natural history questionnaire (yhnq), social readjustment scale for children, neuropsychologic assessment, delayed response tasks, continuous performance task, continuous recognition memory, selective reminding procedures, card sorting tasks, wechsler intelligence scale for children-revised, digit span, digit symbol and mazes paced auditory, serial addition task, purdue pegboard trail making tasks, fluency tasks, rey-osterreith complex figure stanford-binet intelligence scale-fourth edition, physical, neurologic, and neurochemical assessment physical exam (abbreviated), physical and neurological examination for soft signs (paness), 24-hour urinary cortisol and catecholamines, family history and family function assessment of family history, assessment of family functioning. the estimated duration of study is 10 years.

Eligibility criteria:
protocol entry criteria: --disease characteristics-- obsessive compulsive disorder or tourette syndrome meeting diagnostic and statistical manual of mental disorders iv criteria

Keywords: tourette syndrome anxiety disorder disease-related problem/condition neurologic and psychiatric disorders obsessive compulsive disorder oncologic disorders rare disease
diet composition and cardiometabolic risk reduction in adults with sci

Conditions: Obesity; Spinal Cord Injuries; Diabetes

Summary: the purpose of this study is to examine the effectiveness of a low carbohydrate diet on increasing dietary adherence and improving cardiometabolic risk factors among adults with spinal cord injury (sci). seventy overweight/obese adults with sci will be randomized to one of two groups: 1) a reduced carbohydrate diet or 2): a "standard" diet (std). participants will take part in a 6-month behavioral lifestyle intervention implemented through a novel ehealth platform specially designed for individuals with sci.


Eligibility criteria:
inclusion criteria: * sci ≥ 1 year post injury * able to use arms for exercise * bmi of 22-50 kg/m2 * 19-60 years old * reliable access to internet and smartphone * have the ability to converse in english * ability to prepare own food or have input into person responsible for food preparation exclusion criteria: * heart disease * renal disease * active pressure sore * persons on medically restricted diets
effectiveness of ofatumumab in real-world practice

Conditions: Multiple Sclerosis

Summary: this study used a retrospective single cohort pre-post design on optum® clinformatics® data mart (cdm) data from 20 august 2019 to 31 december 2023 (study period). patients with a diagnosis of multiple sclerosis (ms) treated with ofatumumab (omb) between 20 august 2020 (u.s. food and drug administration \[fda\] approval date) and 01 july 2023 (patient identification window) were included in the study population. the date of the first omb claim within the patient identification window was defined as the index date. outcomes, including annualized relapse rate (arr) and ms-related healthcare resource utilization (hcru), were measured across two distinct periods. the pre-index period was defined as the fixed 12-month period prior to the index date, during which demographic and clinical characteristics were also assessed. the post-index period was defined as the variable period of ≥6 months after the index date, extending until the earliest between the end of persistent omb use (defined as last day of omb supply before a gap of ≥60 days or switch to another disease modifying therapy \[dmt\]), discontinuation of enrollment, or end of study period on 31 december 2023.


Eligibility criteria:
inclusion criteria: 1. aged 18 years or older as of the index date corresponding to the initial claim for omb therapy. 2. one claim or more for omb therapy recorded during the patient identification period (index date = date of the first claim for omb). 3. one claim or more with a diagnosis of ms (international classification of diseases, tenth revision \[icd-10\] code g35.xx) any time before the index date and up to 6 months after the index date. 4. continuous healthcare plan enrollment from ≥12 months prior to the index date (pre-index period) to ≥12 months following the index date (post-index period). 5. persistent use of omb therapy throughout the post-index period, defined as the absence of a discontinuation of omb or switch to another ms treatment. exclusion criteria: none.
tempus priority study: a pan-tumor observational study

Conditions: Breast Cancer; Prostate Cancer; Bladder Cancer; Lung Cancer; Brain Cancer; Pancreatic Cancer; Ovarian Cancer; Fallopian Tube Cancer; Peritoneal Cancer; Cancer of Liver; Cancer of Colon; Cancer of Head and Neck; Cancer of Stomach; Cancer of Gastrointestinal Tract; Cancer of Rectum; Cancer of Esophagus; Cancer of Skin; Cancer of Cervix; Cancer of Kidney; Cancer of Larynx; Cancer of Endometrium; Cancer of the Bile Duct; Cancer of Vulva; Cancer of Bone and Connective Tissue; Leukemia; Lymphoma; Spinal Cord Cancer

Summary: observational study that will be collecting clinical and molecular health information from cancer patients who have received comprehensive genomic profiling and meet the specific eligibility criteria outlined for each cohort with the goal of conducting research to advance cancer care and create a dataset that furthers cancer research.

the study will collect combined clinical and molecular health information for cancer patients in the united states from multiple academic medical centers and community oncology practices. participants who agree to join the study will have their molecular profiling results, associated clinical health information, and longitudinal outcomes health information collected by the participating institution for submission to tempus. the specific goal of the study is to create an outcomes-based dataset for future research to improve cancer treatment.

Eligibility criteria:
inclusion criteria: 1. solid or hematologic malignancy. 2. willing and able to provide informed consent where required. 3. has received or will receive genomic profiling. exclusion criteria: 1. individuals without the capacity to consent. 2. prisoners at the time of enrollment.

Keywords: cancer oncology observational genomic profiling precision medicine
evaluation of efficacy and safety of the trilift™ system

Conditions: Skin Laxity; Wrinkle

Summary: single center, single-arm, prospective, open label with before \& after study design.

single center, single-arm, prospective, open label with before \& after study design. the control group will be the subjects before the trilift™ treatment protocol and the experimental group will consist of the same subjects after completion of the trilift™ treatment protocol.

Eligibility criteria:
inclusion criteria: * subject is willing and able to read, understand, and sign the informed consent. * healthy male or female aged 35 - 55 years. * fitzpatrick skin type 1-6. * subject is capable of reading, understanding, and following instructions of the procedure to be applied. * subject is able and willing to comply with the treatment. women in childbearing age who is willing to conduct a pregnancy test prior to each treatment. exclusion criteria: * pregnant, lactating, or plans to become pregnant during the study period or had given birth less than 6 months ago. * concurrent participation in any other study. * subject has a pacemaker or internal defibrillator, implanted neurostimulators or any other internal electric device or patient who had an implant in the past. * subject has metal or other implants in the treatment area (not including dental fillings, implants and crowns). * subject has significant concurrent skin conditions affecting areas to be treated such as sores, bleeding, skin fragility, eczema or psoriasis. * subject has burned, blistered, irritated, or sensitive skin due to excessive fresh tanning in areas to be treated or is unlikely to refrain from excessive tanning during the study. * subject has used oral isotretinoin (accutane® or roaccutan®) within 6 months prior to study. * subject has used topical retinoids in the past 1 month. * history of systemic cancer; premalignant skin lesion or skin concern treatment area. * concurrent conditions such as epilepsy, autoimmune, pulmonary or cardiac disorders. * poorly controlled endocrine disorders such as diabetes. * impaired immune system due to immunosuppressive diseases such as hiv or aids, or use of immunosuppressive medications. * history of collagen disorders, keloid formation or abnormal wound healing. * takes or has taken medications, herbal preparations, food supplements or vitamins that might cause fragile skin or impaired skin healing. * subject has used oral steroids in the past 6 months. * subject has used topical steroids in the past 3 months. * history of bleeding coagulopathies or use of anticoagulants. * use of non-steroidal anti-inflammatory drugs (nsaids, e.g. ibuprofen containing agents) one week before and after each treatment session prior to treatment. * subjects who cannot feel heat to give proper treatment feedback. (nerve damage, etc.) * mental disorders that in the opinion of the investigator would interfere with the ability to comply with the study requirements. * subject has any other medical condition that in the opinion of the investigator warrants exclusion from this study.

Keywords: laxity, facial lifting, wrinkles, rhytids
spanish (spain) validation of a specific symptomatic questionnaire for patients with nocturia

Conditions: Nocturia

Summary: the objective of this study is to validate the spanish (from spain) version of the "nocturia quality of life questionnaire and assess their psychometric properties, using the spanish translation provided by the copyright holder. internal consistency (measured by alpha cronbach coefficient), reproductibility (measured by intraclass correlation coefficient), convergent validity (assessed using other already validate questionnaires such the international prostate symptom score (ipss), king's health and pittsburgh sleeps quality index questionnaires) and discriminant validity will be evaluated.


Eligibility criteria:
inclusion criteria: * men and women * older than 60 years old * one or more voidings overnight exclusion criteria: * sleep disturbances * psychiatric diseases * surgical procedures during the time of study * introduction of new pharmacological treatments during the time of study * inability to complete the questionnaires

Keywords: nocturia symptomatic questionnaire n-qol
the teleneo trial: a multicenter trial of telemedicine for advanced neonatal resuscitations in community hospitals

Conditions: Death; Neonatal; Morbidity;Newborn

Summary: the purpose of this study is to evaluate the impact of real-time audio-video telemedicine consults with a neonatologist (termed teleneonatology) on the early health outcomes of at-risk neonates delivered in community hospitals.

this prospective, multicenter trial will use a stepped wedge cluster randomized study design to evaluate the impact of real-time audio-video telemedicine consults with a neonatologist (termed "teleneonatology") on the risk of early mortality, early morbidity, and delivery room care for at-risk neonates delivered in community hospitals.

Eligibility criteria:
inclusion criteria: group 1: community hospital clinicians to be eligible to participate in this study, an individual must meet all of the following criteria: 1. a clinician who attends newborn resuscitations at a participating community hospital spoke site. 2. provision of informed oral consent prior to any mandatory study specific procedures and analyses. group 2: at-risk outborn neonates to be eligible for this study, a neonate born in a participating community hospital spoke site must meet \*at least one\* of the following inclusion criteria 1. preterm birth at less than 32 weeks' gestation at delivery; or 2. need for advanced resuscitation defined as: 1. positive pressure ventilation (ppv) initiated soon after birth and continued for at least 10 minutes; or 2. placement of an alternative airway (endotracheal tube or laryngeal mask) to provide ppv; or 3. chest compressions. exclusion criteria: group 1: community hospital clinicians none group 2: at-risk outborn neonates a neonate born in a participating community hospital spoke site who meets any of the following criteria will be excluded from the study: 1. birth outside of the hospital birthing center. 2. neonatal transport team present at time of birth and providing resuscitative care. 3. severe congenital anomaly necessitating intensive care or surgery in the first two weeks of life. 4. plan for comfort care (non-resuscitation) following delivery. 5. in-person neonatology-trained physician present for the resuscitation.

Keywords: telemedicine newborn resuscitation
clinical test of blood glucose test strips

Conditions: Diabetes

Summary: blood glucose test strips are tested with the test meters to test the accuracy of the blood pressure monitoring function.


Eligibility criteria:
inclusion criteria: * the patients with blood glucose within the range of iso15197 exclusion criteria: * the patients with blood glucose out of the range of iso15197

Keywords: blood glucose
trem-1 gene polymorphisms

Conditions: Sepsis

Summary: triggering receptor expressed on myeloid cells-1 (trem-1) is a cell surface receptor expressed on neutrophils and monocytes. trem-1 acts to amplify inflammation and serves as a critical mediator of inflammatory response in the context of sepsis. blocking of trem-1 can protect against sepsis in mice. this study was designed to investigate whether trem-1 genomic variations were associated with the prognosis of sepsis. we sequenced 30 sepsis patients with trem-1 gene of four exons by pcr sequencing. when analyzing the results of sequencing, we found two gene polymorphisms located in exon-2 and exon-4, respectively. compare with the ncbi dbsnp and hapmap database, one polymorphisms located in exon-2 is non-synonymous variation rs2234237（ser25thr）, the other one located in exon-4 is synonymous variation rs2234246. two common polymorphisms (rs2234237,rs2234246) within the trem-1 gene were detected in 80 patients with severe sepsis and in 80 healthy control subjects. this study was explored that whether or not polymorphisms detected within the trem-1 gene may play a major role in the predisposition to prognosis of sepsis in a chinese han cohort.


Eligibility criteria:
inclusion criteria: * sepsis met the criteria recommended by 1991 accp/sccm joint meeting and by the diagnostic criteria developed at the 2001 international sepsis definition conference. exclusion criteria: * (1) younger than 18 years of age; (2) acquired immunodeficiency syndrome; (3) reduced polymorphonuclear granulocyte counts (\< 500 μl-1); (4) died within 24h after admission into the icu, or refused to participate in the study, or declined treatment during the period of observation.

Keywords: trem-1; snps; prognosis control（normal person）
a prospective observational study of patients with drug resistant acinetobacter baumannii bacteremia

Conditions: Acinetobacter Bacteraemia

Summary: extensively and multi-drug resistant a. baumannii (ab) represent an emerging threat in hospitals locally and worldwide. there is lack of prospective comparative clinical data to guide optimal strategy for treating such infections. since it remains unclear how to treat bacteremia caused by ab, the present study aims to enroll patients at multiple sites with extensively drug resistant acinetobacter species bacteremia receiving different combination therapy to assess treatment outcomes and analyze risk factors associated with mortality.

patients with ab bacteremia receiving antimicrobial therapy are eligible for this multicenter study. antimicrobial agents are decided at the discretion of the attending clinical team. clinical data to be collected include patient demographics (age, gender, underlying diseases, pitt bacteremia score \[20\], duration of icu stay and hospitalization before the day of first positive blood culture, central venous catheterization), antimicrobial agents on the day of bacteremia, regimens and durations of combination therapy after enrollment, and outcomes (sequential quantification change of blood a. baumannii polymerase chain reaction \[pcr\], survival at day 30 after enrollment, and adverse drug reactions of antimicrobial agents). blood sample will be collected on the day of enrollment (day 0), day 1, 2, 3 and 7 for pcr quantification of a. baumannii and for genospecies identification. primary end points are the interval from study enrollment to negative blood a. baumannii pcr and blood sterilization. secondary end points are survival at 14 and 30-day after enrollment, adverse drug reactions of antimicrobial agents, and risk factors for survival at 30-day after enrollment. inclusion criteria: 1. adults \>16 years 2. with blood culture isolate(s) a. baumannii. 3. informed consent gained. exclusion criteria: 1. second/repeat episodes of bacteremia 2. patients who could not or did not receive antimicrobial treatment 3. patient not admitted to hospital.

Eligibility criteria:
inclusion criteria: * adults ( \>16 years) * with blood culture isolate(s) a. baumannii * informed consent gained exclusion criteria: * second/repeat episodes of bacteremia * patients who could not or did not receive antimicrobial treatment * patient not admitted to hospital

Keywords: bloodstream infections acinetobacter drug resistant acinetobacter baumannii bacteremia
erector spinae plane block in congenital heart disease patients

Conditions: Congenital Heart Disease in Children; Neurologic Complication

Summary: pediatric cardiac patients undergoing surgical anesthesia are at an increased risk of poor neurologic outcome (20-50%). unattenuated anesthetic exposure and pain contributes to physiologic perturbations that may increase neurologic morbidity. because of the often-large exposure to anesthetic agents in these cardiac children, at such a young age and the potential modifying anesthetic practice that could lead to improved neurodevelopmental outcomes and surgical recovery is paramount. regional anesthesia such as thoracic epidurals provide effective analgesia and reduced intraoperative anesthetic needed but carry devastating sequelae neurological risks of epidural hematomas after anticoagulation during cardiopulmonary bypass (cpb). recently, a newly described erector spinae plane block (espb) is superficial to neuraxial or vascular structures, providing opportunity to be placed with less risk for surgery requiring cpb. this block has been described as effective regional anesthesia for adult cardiac surgery.


Eligibility criteria:
inclusion criteria: * neonates of at least 32 weeks of gestation, infants and children admitted to the lucile packard children's hospital for treatment of cyanotic or non-cyanotic heart disease requiring surgical intervention. * admitting diagnosis of cyanotic or non-cyanotic heart disease exclusion criteria: * neonates less than 32 weeks of gestational age * any documented central nervous system malformations. * any potential subject requiring unexpected postoperative extracorporeal membrane oxygenation (ecmo) support

Keywords: erector spinae plane blockade pediatric congenital heart disease